You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

3 Results
Drug
Other Name(s): Busulfex® , Myleran®
Jun 2019
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
    triptorelin
ODB - General Benefit
    bicalutamide
Jan 2018
Guidelines and Advice
Status: In-Review
ID: RR 21-5
Version: n/a
Jan 2019